artemether has been researched along with Carcinoma, Non-Small Cell Lung in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Badanthadka, M; Chokshi, N; Khatri, H; Patel, BM; Patel, MM; Rawal, S | 1 |
| Chen, J; Huang, X; Li, X; Ma, M; Tao, C; Wu, Z; Xiao, T; Zeng, Q | 1 |
2 other study(ies) available for artemether and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Fabrication and in vivo evaluation of ligand appended paclitaxel and artemether loaded lipid nanoparticulate systems for the treatment of NSCLC: A nanoparticle assisted combination oncotherapy.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Artemether; Biological Availability; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Carriers; Drug Compounding; Drug Liberation; Drug Stability; Folic Acid; Humans; Lipids; Lung Neoplasms; Male; Mice, Inbred BALB C; Nanoparticles; Paclitaxel; Polyethylene Glycols; Rats, Sprague-Dawley; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Artemether Attenuates the Progression of Non-small Cell Lung Cancer by Inducing Apoptosis, Cell Cycle Arrest and Promoting Cellular Senescence.
Topics: A549 Cells; Apoptosis; Artemether; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinases; Cyclins; Disease Progression; DNA Damage; Down-Regulation; Humans; Inhibitor of Apoptosis Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Tumor Suppressor Protein p53; Up-Regulation | 2019 |